Efficacy and safety of neoadjuvant therapy combined with immunotherapy in MMR‑proficient/microsatellite stable non‑metastatic rectal cancer: a systematic review and meta‑analysis
Open Access
- 15 December 2025
- journal article
- review article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (1) , 9
Abstract
To comprehensively evaluate the efficacy and safety of neoadjuvant therapy combined with immunotherapy in patients with MMR-proficient/microsatellite stable (pMMR/MSS) non-metastatic rectal cancer. Major databases, including PubMed, Web of Science, Cochrane Library, Embase, ASCO, and ESMO, were systematically searched for studies on neoadjuvant therapy combined with immunotherapy in pMMR/MSS non-metastatic rectal cancer, up to April 2025. Statistical analysis utilized Stata 18 software, calculating outcomes with pathological complete response (pCR), major pathological response (MPR), clinical complete response (cCR), R0 resection, anal preservation rate, and the incidence of adverse events. Heterogeneity and publication bias were evaluated using I² and funnel plots. A total of 21 trial cohorts from 18 studies were included in the meta-analysis. The overall pooled pCR, MPR, and cCR rates were 35% (95% CI: 30-40%, I2 = 48.8%, p < 0.001), 58% (95% CI: 51-64%, I2 = 69.0%, p < 0.001), and 19% (95% CI: 11-26%, I2 = 86.2%, p < 0.001), respectively. An R0 resection rate of 99% (95% CI: 99-100%, I2 = 51.8%) and an anal preservation rate of 84% (95% CI: 79-90%, I2 = 75.1%) were also achieved. Regarding safety, grade ≥ 3 immune-related adverse events (irAEs) and surgery-related adverse events (srAEs) occurred at rates of 1% and 6%, respectively. Notably, subgroup analyses demonstrated that short-course chemoradiotherapy (SCRT) yielded significantly higher pCR (46% vs. 31%, p < 0.001) and MPR (66% vs. 53%, p = 0.02) rates compared to Long-course chemoradiotherapy (LCRT), with a trend toward superior cCR (25% vs. 15%, p = 0.08). Comparison among neoadjuvant therapy (NAT) protocols revealed comparable pCR rates across consolidation (36%), induction (34%), and concurrent (35%) strategies (p = 0.97), although the MPR rate differed significantly (p < 0.05). Additionally, subgroup analysis based on immune checkpoint inhibitor type demonstrated similar efficacy between monotherapy (pCR: 36%) and dual therapy with PD-1 plus CTLA-4 inhibitors (pCR: 29%), with no statistically significant differences observed across endpoints. Neoadjuvant therapy combined with immunotherapy in pMMR/MSS non-metastatic rectal cancer demonstrates promising efficacy-with high response rates, excellent R0 resection, and favorable anal preservation outcomes-and an acceptable safety profile. The improved outcomes observed with short-course radiotherapy underscore its potential role in optimizing treatment. However, the heterogeneous nature of current evidence and study designs highlight the need for further high-quality randomized trials.Keywords
This publication has 37 references indexed in Scilit:
- 243P Neoadjuvant XELOX chemotherapy with or without cadonilimab in locally advanced pMMR rectal cancer: Preliminary results from a randomized, open-label phase II trialAnnals of Oncology, 2024
- 249P The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and cadonilimab for locally advanced rectal cancer: The preliminary findings of prospective, multicenter phase II trialAnnals of Oncology, 2024
- Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal CancerJAMA Surgery, 2024
- Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal CancerJAMA Oncology, 2023
- 599P R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)Annals of Oncology, 2023
- 595P The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)Annals of Oncology, 2023
- P-172 VOLTAGE cohort D: Preoperative chemoradiotherapy followed by consolidation nivolumab plus ipilimumab in patients with locally advanced rectal cancerAnnals of Oncology, 2023
- Immune Checkpoint Inhibitors in pMMR/MSS Colorectal CancerJournal of Gastrointestinal Cancer, 2023
- Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancerClinical and Translational Oncology, 2023
- Use of Total Neoadjuvant Therapy for Locally Advanced Rectal CancerJAMA Oncology, 2021